ClinicalTrials.gg
Active, not recruitingNCT04784715Updated Oct 22, 2026

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

A Phase 3 interventional study of Trastuzumab deruxtecan and Placebo in Breast Cancer; HER2-positive; Metastatic, sponsored by AstraZeneca. Active, not recruiting at 283 sites in 27 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 22, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,157
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
2nd of 58
1,157 · median 139
Started
2021
with 2 others
Phase 3
12 of 58
3 open now
Primary completion
2027-05
later than 21 of 44 live
Registered
20th of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 21 of the 44 other live ones, and was the 20th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

Read the detailed description

Eligible participants will be those diagnosed with HER2-positive (IHC 3+ or ISH+), metastatic breast cancer, who have received no prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer.

The study aims to evaluate the efficacy, and safety of trastuzumab deruxtecan, alone or with pertuzumab, compared with the standard of care treatment (taxane [docetaxel or paclitaxel], trastuzumab and pertuzumab). This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the cancer affects patients' quality of life.

03

Conditions studied

  • Breast Cancer; HER2-positive; Metastatic

Keywords

  • Breast Neoplasms; Breast Diseases; Trastuzumab; Antineoplastic Agents, Phytogenic; Anti-drug conjugate; Molecular Mechanisms of Pharmacological Action;
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be ≥18 years of age
  • documented breast cancer that:

    1. is advanced or
    2. is locally assessed and prospectively centrally confirmed as -positive (IHC3+ or ISH+)
    3. is documented by local testing as hormone receptor (HR)-positive or HR-negative disease in the metastatic setting
  • No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis.
  • Has protocol-defined adequate organ and bone marrow function
  • performance status 0 or 1

Key Exclusion Criteria:

  • Ineligible for any of the agents on the study.
  • Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with subject's participation or study results
  • Patients with spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive or treated brain metastases that are no longer symptomatic may be included in the study.
  • Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,157 participants (actual)

Study arms

  • Experimental
    Arm A

    Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo

    Drug: Trastuzumab deruxtecan · Drug: Placebo

  • Experimental
    Arm B

    Trastuzumab deruxtecan (T-DXd) plus pertuzumab

    Drug: Trastuzumab deruxtecan · Drug: Pertuzumab

  • Active comparator
    Arm C

    Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab)

    Drug: Taxane · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Administered by intravenous infusion

    Also known as: DS-8201a; T-DXd

  • DrugPlacebo

    Administered by intravenous infusion

  • DrugTaxane

    Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion

  • Administered by intravenous infusion

  • Administered by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment

    Defined as time from date of randomisation until the date of objective radiological disease progression according to Blinded Independent Central Review (BICR) using RECIST 1.1 or death by any cause.

    Time frame: Until progression or death, assessed up to approximately 60 months

Secondary outcomes

  1. Progression Free Survival (PFS) by Investigator assessment

    Defined as time from date of randomisation until the date of objective radiological disease progression according to Investigator using RECIST 1.1 or death by any cause.

    Time frame: Until progression or death, assessed up to approximately 60 months

  2. Overall Survival (OS)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Until death, assessed up to approximately 104 months

  3. Objective Response Rate (ORR) by BICR and Investigator assessment

    ORR is defined as The proportion of participants who have a complete response (CR) or partial response (PR) based on BICR and investigator assessment using RECIST 1.1.

    Time frame: Until progression or death (in the absence of progression), assessed up to approximately 60 months

  4. Duration of Response (DoR) by BICR and Investigator Assessment

    DoR is defined as the time from date of first detection of objective response until the date of objective radiological disease progression according to BICR and investigator assessment using RECIST 1.1 or death in the absence of progression.

    Time frame: Until progression or death (in the absence of progression), assessed up to approximately 60 months

  5. Time to second progression or death (PFS2) by Investigator assessment

    PFS2 is defined as the time from randomisation until the date of tumor progression on next-line treatment (the earliest of the progression event subsequent to first subsequent anticancer therapy after the first progression) or death from any cause; second progression will be defined according to local standard clinical practice.

    Time frame: Assessed up to approximately 104 months

  6. To assess the effect of T-DXd ± pertuzumab relative to THP in terms of patient-reported pain in participants with HER2 positive, first-line mBC'.

    Pain progression: Time to sustained deterioration of European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Pain Scale. Scores range from 0-100 based on 2 items with responses ranging from 1-4. A lower score would mean better outcome.

    Time frame: Assessed up to approximately 60 months

  7. To assess patient-reported treatment tolerability

    Proportion of participants experiencing treatment related symptoms as measured by selected items from the European Organisation for Research and Treatment of Cancer, general cancer module (EORTC QLQ-C30), score of 1-4. A lower score would mean better outcome.

    Time frame: Assessed up to approximately 60 months

  8. To assess patient-reported treatment tolerability

    Proportion of patients reporting different levels of overall tolerability as measured by the Patient Global Impression of Treatment Tolerability (PGI-TT), score of 0-4. A lower score would mean a better outcome.

    Time frame: Assessed up to approximately 60 months

  9. To assess patient-reported treatment tolerability

    Proportion of participants experiencing treatment related symptoms as measured by selected items from the European Organisation for Research and Treatment of Cancer, breast cancer module (EORTC QLQ-BR45), score of 1-4. A lower score would mean better outcome.

    Time frame: Assessed up to approximately 60 months

  10. To assess patient-reported treatment tolerability

    Proportion of participants experiencing treatment related symptoms as measured by selected items from the Patient-Reported Outcomes- Common Terminology Criteria for Adverse Events (PRO-CTCAE). PRO-CTCAE responses are scored from 0 to 4 (or 0/1 for absent/present). A lower score would mean a better outcome.

    Time frame: Assessed up to approximately 60 months

  11. To assess patient-reported treatment tolerability

    The proportion of participants with maintained or improved physical function while on treatment, based on the EORTC QLQ-C30 Physical Functioning scale. Scores range from 0-100, based on 5 items with responses ranging from 1-4. A higher score would mean a better outcome.

    Time frame: Assessed up to approximately 60 months

  12. Serum concentration of trastuzumab deruxtecan and pertuzumab

    Determination of trastuzumab deruxtecan and pertuzumab concentrations in serum.

    Time frame: Up to Cycle 6, approximately Week 18; each cycle is 21 days

  13. Immunogenicity of trastuzumab deruxtecan.

    Number and percentage of participants who develop anti-drug antibody (ADA) for trastuzumab deruxtecan.

    Time frame: Up to follow-up period, approximately 60 months

  14. Safety and tolerability of trastuzumab deruxtecan, alone or with pertuzumab

    Number of AEs according to NCI-CTCAE Version 5.0 per each treatment arm

    Time frame: Assessed up to approximately 60 months

07

Study locations

283 sites
  • Research Site
    Tucson, Arizona 85711, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Longmont, Colorado 80501, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Palm Bay, Florida 32909, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Louisville, Kentucky 40241, United States
  • Research Site
    Silver Spring, Maryland 20904, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Jackson, Mississippi 39213, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Shirley, New York 11967, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Dallas, Texas 75203, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Denton, Texas 76201, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    San Antonio, Texas 78240, United States
  • Research Site
    Shenandoah, Texas 77380, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Roanoke, Virginia 24014, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Buenos Aires, C1125ABD, Argentina
  • Research Site
    CABA, 1414, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    Caba, C1118AAT, Argentina
  • Research Site
    Capital Federal, C1417DTB, Argentina
  • Research Site
    Cipolletti, 8234, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    Rosario, S2002KDS, Argentina
  • Research Site
    San Salvador de Jujuy, 4600, Argentina
  • Research Site
    Brussels, 1160, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Goiânia, 74000-000, Brazil
  • Research Site
    Londrina, 86015-520, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Ribeirão Preto, 14015-130, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Sorocaba, 18030-005, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Montreal, Quebec H3T 1M5, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Ste-Foy, Quebec G1V 4G2, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400016, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Dalian, 116011, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Qingdao, 266100, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenzhen, 518036, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430022, China

Showing the first 100 of 283 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Sendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 5;394(6):551-562. doi: 10.1056/NEJMoa2508668. Epub 2025 Oct 29. PubMed 41160818 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for May 2027, 72 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 72 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → May 2027, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2021
First posted
Mar 5, 2021
StartActual
Apr 26, 2021
Primary completionEst.
May 3, 2027was Nov 2026
CompletionEst.
Dec 31, 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Site · Gūrgaon, India
Show 1 removed
  • Research Site · Gurgaon, India
Oct 22, 2026
Primary completion
Nov 11, 2026→May 3, 2027
Oct 22, 2026
Study completion
Dec 30, 2029→Dec 31, 2029
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added, 1 site removed
    Show site
    • Research Site · Gūrgaon, India
    Show 1 removed
    • Research Site · Gurgaon, India
    Primary completion Nov 11, 2026→May 3, 2027
    Study completion Dec 30, 2029→Dec 31, 2029
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04784715
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Apr 26, 2021
Primary completion
May 3, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Pertuzumab

Start the discussion